Ironwood Pharmaceuticals Inc IRWD:NASDAQ

Last Price$13.40NASDAQ Previous Close - Last Trade as of 4:00PM ET 3/18/19

Today's Change-0.22(1.62%)
Bid (Size)$12.50 (2)
Ask (Size)$15.30 (2)
Day Low / High$13.10 - 14.13
Volume3.9 M

View Pharmaceuticals: Other IndustryPeer Comparison as of 03/18/2019


Ironwood Pharmaceuticals Inc ( NASDAQ )

Price: $13.40
Change: -0.22 (1.62%)
Volume: 3.9 M
4:00PM ET 3/18/2019

MyoKardia Inc ( NASDAQ )

Price: $53.86
Change: +1.25 (2.38%)
Volume: 269.5 K
4:00PM ET 3/18/2019

Aerie Pharmaceuticals Inc ( NASDAQ )

Price: $47.09
Change: +0.11 (0.23%)
Volume: 409.1 K
4:00PM ET 3/18/2019

Supernus Pharmaceuticals Inc ( NASDAQ )

Price: $38.37
Change: +0.37 (0.97%)
Volume: 469.3 K
4:00PM ET 3/18/2019

Portola Pharmaceuticals Inc ( NASDAQ )

Price: $33.05
Change: -0.24 (0.72%)
Volume: 919.9 K
4:00PM ET 3/18/2019

Read more news Recent News

Insider Selling at Ironwood Pharmaceuticals (IRWD) Continues with Significant Sale
10:17PM ET 3/11/2019 MT Newswires

One Ironwood Pharmaceuticals insider Dr Mark G Currie, Officer, today, sold 275,000 shares having a market value of approximately $3,647,820, as disclosed...

Insider Trends: Insider Sale Reduces 90-Day Buy Trend at Ironwood Pharmaceuticals
5:56PM ET 3/08/2019 MT Newswires

Dr Mark G Currie, Chief Scientific Officer, sold 275,000 shares of Ironwood Pharmaceuticals (IRWD) on Mar 07, 2019, for $3,647,820. Dr Currie, subsequent...

Analyst Actions: HC Wainwright Upgrades Ironwood Pharmaceuticals to Neutral From Sell; Lifts PT to $14 From $11.5
10:19AM ET 2/25/2019 MT Newswires

Ironwood Pharmaceuticals' (IRWD) average rating among analysts is a hold. Price: 14.51, Change: +0.26, Percent Change: +1.82 ...

Insider Trends: 90-Day Insider Buying Trend Slowed with Sale of Ironwood Pharmaceuticals Shares
4:54PM ET 2/22/2019 MT Newswires

On Feb 20, 2019, Chief Legal Officer, Halley E Gilbert, executed a sale of 10,242 shares in Ironwood Pharmaceuticals (IRWD) for $146,564. Gilbert, after...

Company Profile

Business DescriptionIronwood Pharmaceuticals, Inc. is a commercial biotechnology company, which engages in the discovery, commercialization, and development of medicines. Its products include linaclotide, a guanylate cyclase type-C agonist which treats patients irritable bowel syndrome with constipation and chronic constipation. The company was founded by Peter M. Hecht, Eric F. Summers, G. Todd Milne, Brian M. Cali, Joseph C. Cook Jr., and Gina Bornino Miller in 1998 and is headquartered in Cambridge, MA. View company web site for more details
Address301 Binney Street
Cambridge, Massachusetts 02142
Number of Employees515
Recent SEC Filing03/14/20193
Chief Executive Officer & DirectorPeter M. Hecht
Chief Operating OfficerWilliam I. Huyett
Chief Financial Officer, Treasurer & Senior VPGina R. Consylman
Chief Scientific Officer, President-R&D, SVPMark G. Currie

Company Highlights

Price Open$13.61
Previous Close$13.62
52 Week Range$9.07 - 21.20
Market Capitalization$2.1 B
Shares Outstanding154.6 M
SectorHealth Technology
IndustryPharmaceuticals: Other
Next Earnings Announcement05/07/2019

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.18
Beta vs. S&P 500N/A
Revenue$346.6 M
Net Profit Margin-81.46%
Return on Equity247.87%

Analyst Ratings as of 03/01/2019

Consensus RecommendationConsensus Icon
Powered by Factset